Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Mish's Global Economic Trend Analysis -- Ignore unavailable to you. Want to Upgrade?

To: Elroy Jetson who wrote (38976)	10/11/2005 7:12:28 PM
From: NOW	Respond to of 116555

"Osterholm and other experts have long been complaining that there are not sufficient hospital beds, equipment or trained workers to cope with a major epidemic. "The one thing I worry desperately about it is the impact of overreliance on neuraminidase inhibitors," he said. There are two drugs in the class -- Roche and Gilead's Tamiflu, known generically as oseltamivir, and GlaxoSmithKline's Relenza. They work to reduce the severity of annual influenza and may prevent infection if used at the right time. Tests suggest they also work against H5N1, but no one knows how well. "I think that potentially neuraminidase inhibitors may work if you are already on them as prophylaxis (prevention)," Osterholm said. That would mean taking them daily for days or weeks. "That means that very, very limited supply is going to become a lot more limited."